AstraZeneca has announced it will not pursue development of an investigational drug, NXY-059, also known as Cerovive, after results of a phase 3 trial showed no significant reduction in stroke-related disability with treatment vs placebo.
Medscape Medical News
Susan Jeffrey
More...